During an event organized by the National Academies of Sciences, Engineering and Medicine, titled “Exploring Psychedelics & Entactogens to Treat Psychiatric Disorders,” two officials noted the challenges scientists face in conducting research into Schedule I substances such as psychedelics, reported Marijuana Moment.
“The scheduling process makes it extremely hard to do research and it has slowed down the process enormously,” said Nora Volkow, psychiatrist, and director of the National Institute on Drug Abuse (NIDA).
